Current COVID-19 vaccines induce robust cellular immunity against Omicron variant

A highly mutated version of SARS-CoV-2, the virus that causes COVID-19, the Omicron variant has been shown to cause breakthrough infections among the vaccinated thanks to its ability to evade the virus-killing neutralizing antibodies that the body makes in response to getting vaccinated.

However, a new study by researchers at Beth Israel Deaconess Medical Center (BIDMC) demonstrated that cellular immunity - or the production of protective immune cells, such as so-called killer and memory cells - induced by current COVID-19 vaccines provided robust protection against severe disease caused by both the Delta and Omicron variants. The team assessed samples from 47 individuals vaccinated with either the Johnson & Johnson or Pfizer-BioNTech vaccines. The findings are published in Nature.

"Our data provide immunological context for the observation that current vaccines still provide robust protection against severe disease and hospitalization due to the Omicron variant despite substantially reduced neutralizing antibody responses and increased breakthrough infection," said corresponding author Dan H. Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at BIDMC, whose team was involved in the development of the Johnson & Johnson vaccine.

Using samples from uninfected individuals who received either the Johnson & Johnson or Pfizer-BioNTech vaccines, Barouch and colleagues measured CD8+ T cell and CD4+ T cell responses to the original, Delta and Omicron strains of the SARS-CoV-2 virus after one month and then again after eight months following final vaccination. They likewise assessed antibody responses to the variants at one and eight months out.

Consistent with previous reports, the scientists observed minimal cross-reactive Omicron-specific neutralizing antibodies. In contrast, the team’s data suggested that Omicron-specific CD8+ T cell responses were more than 80 percent cross-reactive with the CD8+ T cell response to the original strain of the virus. Similarly, more than 80 percent of Omicron-specific CD4+ T cells demonstrated cross-reactivity, although responses could vary among individuals, the scientists note.

"Given the role of CD8+ T cells in clearance of viral infections, it is likely that cellular immunity contributes substantially to vaccine protection against severe SARS-CoV-2 disease," said Barouch who is also professor of medicine at Harvard Medical School and a member of the Ragon Institute of MGH, MIT, and Harvard. "This may be particularly relevant for Omicron which dramatically evades neutralizing antibody responses."

Liu J, Chandrashekar A, Sellers D, Barrett J, Jacob-Dolan C, Lifton M, McMahan K, Sciacca M, VanWyk H, Wu C, Yu J, Collier AY, Barouch DH.
Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron.
Nature. 2022 Jan 31. doi: 10.1038/s41586-022-04465-y

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...